NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013399" target="_blank" >RIV/00023736:_____/22:00013399 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1080/2162402X.2022.2073050" target="_blank" >https://doi.org/10.1080/2162402X.2022.2073050</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2022.2073050" target="_blank" >10.1080/2162402X.2022.2073050</a>

Result language
angličtina
Original language name
NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia
Original language description
The immune system is important for elimination of residual leukemic cells during acute myeloid leukemia (AML) therapy. Anti-leukemia immune response can be inhibited by various mechanisms leading to immune evasion and disease relapse. Selected markers of immune escape were analyzed on AML cells from leukapheresis at diagnosis (N = 53). Hierarchical clustering of AML immunophenotypes yielded distinct genetic clusters. In the absence of DNMT3A mutation, NPM1 mutation was associated with decreased HLA expression and low levels of other markers (CLIP, PD-L1, TIM-3).
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)